SEC Form 4 · accession 0001127602-16-044967
ARIAD PHARMACEUTICALS INC · ARIA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward M Fitzgerald
Officer — Executive VP, CFO
Period of report
Mar 1, 2016
Accepted (ET)
Mar 3, 2016 · 8:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000884731
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2016 | M | 19,250 | $0.00 | A | 324,576 | D | |
| Common StockF3 | Mar 3, 2016 | S | 9,625 | $6.1159 | D | 314,951 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance stock unitF4,F5 | — | Mar 1, 2016 | M | 19,250 | D | — | — | Common Stock | 19,250 | 19,250 | D |
| Performance stock unitF4,F5 | — | Mar 1, 2016 | A | 38,500 | A | — | — | Common Stock | 38,500 | 38,500 | D |
Explanation of responses
- F1Shares were acquired upon vesting of performance stock units awarded on January 31, 2014.
- F2Represents shares sold to satisfy withholding tax requirements, pursuant to a Rule 10b5-1 trading plan.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.04 to $6.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Security and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
- F4Each performance stock unit represents a right to receive one share of ARIAD common stock.
- F5The performance stock units vest as to 50% of the award on 3/1/2016 and 50% of the award on 3/1/2017.